ERBB2 and neoplasm: In the MyPathway trial, we previously demonstrated the antitumor activity of P+T, leading to incorporation of this regimen into both the ESMO Clinical Practice Guidelines and the NCCN Guidelines®.8, 34 Here we demonstrate that the majority of patients with ERBB2-amplified CRC have ERBB2 amplification on ctDNA, but that ctDNA ERBB2 detection is at least in part associated with tumor burden.